NASDAQ:SCNI Scinai Immunotherapeutics Q4 2024 Earnings Report $0.46 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.47 +0.01 (+2.12%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Scinai Immunotherapeutics EPS ResultsActual EPS-$10.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AScinai Immunotherapeutics Revenue ResultsActual Revenue$0.21 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AScinai Immunotherapeutics Announcement DetailsQuarterQ4 2024Date5/7/2025TimeAfter Market ClosesConference Call DateTuesday, May 6, 2025Conference Call Time6:00PM ETUpcoming EarningsScinai Immunotherapeutics' Q1 2026 earnings is estimated for Tuesday, July 7, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Scinai Immunotherapeutics Earnings HeadlinesComparing Scinai Immunotherapeutics (NASDAQ:SCNI) & Nuvalent (NASDAQ:NUVL)May 22, 2026 | americanbankingnews.comScinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO FacilityMay 20, 2026 | prnewswire.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 26 at 1:00 AM | Porter & Company (Ad)Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit EuropeMay 15, 2026 | prnewswire.comScinai Immunotherapeutics Announces $2.61 Million Private Placement FinancingApril 24, 2026 | prnewswire.comScinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 PrioritiesApril 6, 2026 | prnewswire.comSee More Scinai Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email. Email Address About Scinai ImmunotherapeuticsScinai Immunotherapeutics (NASDAQ:SCNI) Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors. Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts. These partnerships support lead optimization, biomarker identification and the generation of preclinical efficacy and safety data in preparation for eventual clinical evaluation. Headquartered in the United States, Scinai Immunotherapeutics conducts its research and development activities primarily in North America while pursuing strategic alliances to extend its presence into European and Asian markets. The company remains focused on translating its scientific platform into robust therapeutic options, underpinned by rigorous preclinical validation and translational research initiatives.View Scinai Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half Upcoming Earnings Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
